Compare DFLI & NMTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFLI | NMTC |
|---|---|---|
| Founded | 2020 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.0M | 39.5M |
| IPO Year | N/A | 2010 |
| Metric | DFLI | NMTC |
|---|---|---|
| Price | $2.05 | $4.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.25 | ★ $11.90 |
| AVG Volume (30 Days) | ★ 378.4K | 187.3K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,097,692.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $51.17 | $31.90 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 163.47 |
| 52 Week Low | $0.15 | $0.55 |
| 52 Week High | $5.15 | $5.40 |
| Indicator | DFLI | NMTC |
|---|---|---|
| Relative Strength Index (RSI) | 48.28 | 87.04 |
| Support Level | $1.56 | $0.69 |
| Resistance Level | $2.24 | N/A |
| Average True Range (ATR) | 0.16 | 0.24 |
| MACD | 0.04 | 0.38 |
| Stochastic Oscillator | 49.98 | 87.06 |
Dragonfly Energy Holdings Corp is a manufacturer of non-toxic deep cycle lithium-ion batteries that are designed to displace lead acid batteries in a number of different storage applications and end markets including RV, marine vessel, and solar and off-grid industries, with disruptive solid-state cell technology currently under development. The company's deep cycle lithium iron phosphate ("LFP") batteries provide numerous advantages compared to incumbent products, such as lead-acid batteries. LFP batteries are non-toxic and environmentally friendly, do not rely on scarce or controversial metals, and are a cost-effective storage solution.
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.